Mirel's score

Mirel's Score is a clinical tool used to predict the risk of pathological fractures in patients with metastatic bone disease. It was developed by Dr. Mirel in 1989 and has been widely used in clinical practice since then.

Overview

The Mirel's Score is calculated based on four factors: the site of the lesion, the nature of the lesion, the size of the lesion, and the presence of pain. Each factor is scored from 1 to 3, with a total score ranging from 4 to 12. A score of 9 or above is considered high risk for pathological fracture.

Calculation

The Mirel's Score is calculated as follows:

• Site of the lesion: Upper limb (proximal humerus, femur) = 2 points; Lower limb (distal to the knee) = 3 points; Other sites = 1 point.
• Nature of the lesion: Blastic (bone-forming) = 1 point; Mixed (both bone-forming and bone-destroying) = 2 points; Lytic (bone-destroying) = 3 points.
• Size of the lesion: Less than 1/3 of the bone diameter = 1 point; 1/3 to 2/3 of the bone diameter = 2 points; More than 2/3 of the bone diameter = 3 points.
• Presence of pain: Mild or no pain = 1 point; Moderate pain = 2 points; Severe pain or functional impairment = 3 points.

Clinical Use

The Mirel's Score is used to guide treatment decisions in patients with metastatic bone disease. A high score may indicate the need for surgical intervention to prevent a pathological fracture, while a low score may suggest that conservative management is appropriate.

Limitations

While the Mirel's Score is a useful tool, it has some limitations. It does not take into account the patient's overall health status or the specific type of cancer. Additionally, it is based on subjective assessments of pain and lesion size, which can vary between observers.

See Also

• Pathological fracture
• Metastatic bone disease
• Blastic lesion
• Lytic lesion

Mirel's score Resources
Latest articles Most recent articles Ongoing trials	Wikipedia